ME/CFS & Prostate Cancer -Raltegravir Inhibitor XMRV

[Guest guest]

http://bit.ly/aaarO0

URO TODAY

Raltegravir is a potent inhibitor

of XMRV, a virus implicated in

prostate cancer and chronic

fatigue syndrome

Wednesday, 21 April 2010

Singh IR, Gorzynski JE, Drobysheva D,

Bassit L, Schinazi RF.

Department of Pathology, University of Utah, Salt

Lake City, Utah, United States of America.

ila.singh@...

This email address is being protected from spam

bots, you need Javascript enabled to view it

Reference: PLoS One. 2010 Apr 1;5(4):e9948.

doi: 10.1371/journal.pone.0009948

PubMed Abstract

PMID: 20376347

Xenotropic murine leukemia-related retrovirus

(XMRV) is a recently discovered retrovirus that has

been linked to human prostate cancer and chronic

fatigue syndrome (CFS).

Both diseases affect a large fraction of the world

population, with prostate cancer affecting one in six

men, and CFS affecting an estimated 0.4 to 1% of

the population.

Forty-five compounds, including twenty-eight drugs

approved for use in humans, were evaluated against

XMRV replication in vitro.

We found that the retroviral integrase inhibitor,

raltegravir, was potent and selective against XMRV

at submicromolar concentrations, in MCF-7 and

LNCaP cells, a breast cancer and prostate cancer cell

line, respectively.

Another integrase inhibitor, L-000870812, and two

nucleoside reverse transcriptase inhibitors,

zidovudine (ZDV), and tenofovir disoproxil fumarate

(TDF) also inhibited XMRV replication.

When combined, these drugs displayed mostly

synergistic effects against this virus, suggesting that

combination therapy may delay or prevent the

selection of resistant viruses.

If XMRV proves to be a causal factor in prostate

cancer or CFS, these discoveries may allow for

rational design of clinical trials.